Kalaris Therapeutics Inc

Research Kalaris Therapeutics Inc (KLRS) on Bullrun: market cap USD 100.28M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerKLRS
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 100.28M
• Financial periodFY2025
• Net income-USD 43.43M
• Free cash flow-USD 38.57M

Valuation Snapshot

latest market cap is USD 100.28M.

About Kalaris Therapeutics Inc

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc.

Frequently asked questions

What is Kalaris Therapeutics Inc's market cap?

Kalaris Therapeutics Inc's market capitalization is USD 100.28M.

What does Kalaris Therapeutics Inc do?

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases.